Dr Ana Kiess speaks to ecancer about the RAVENS phase II randomised trial.

This study examines the impact of stereotactic body radiotherapy with or without radium 223 on men with oligometastatic hormone-sensitive prostate cancer.

Patients are randomised to receive either treatment alone or in combination.

Results show no significant delay in disease progression with the addition of radium 223.

The study highlights radium's mechanism and its potential benefits in higher volume disease while also identifying key prognostic biomarkers.